Physiotulle vs Urgotul in the Treatment of Leg Ulcer

NCT ID: NCT01238419

Last Updated: 2011-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

188 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the pain at removal of Physiotulle dressing in comparison with that of Urgotul dressing in patients presenting a venous (or predominantly) venous leg ulcer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leg Ulcers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Physiotulle

Group Type EXPERIMENTAL

Physiotulle

Intervention Type DEVICE

Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline

Urgotul

Group Type PLACEBO_COMPARATOR

URGOTUL

Intervention Type DEVICE

Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Physiotulle

Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline

Intervention Type DEVICE

URGOTUL

Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient of either sex over 18 who have not been declared legally incompetent and who having given his written informed consent
* Patient with venous or predominantly venous leg ulcer (ankle-brachial index \> 0.8)
* Patient with venous or predominantly venous leg ulcer in granulation phase (granulation tissue \> 70 %)
* Patient with venous or predominantly venous leg ulcer with low exsudate
* Patient with venous or predominantly venous leg ulcer with a wound surface between 4 cm² and 170 cm²
* Patient with venous or predominantly venous leg ulcer that has been treated with an appropriate compression in the two weeks prior to inclusion
* Patient available to be monitored for at least 4 weeks
* Patient able to answer questionnaires and particularly to evaluate his pain

Exclusion Criteria

* Patient whose leg ulcer is locally infected (At least 3 of 5 clinical signs suggestive of infection \*)\* 5 signs suggestive of infection: pain, exsudate, smell, oedema, erythema
* Patient requiring an analgesic treatment for the care (before dressing removal)
* Patient whose ulcer belongs to angiodermatitis type or demonstrates a vasculitis
* Patient with arterial ulcer
* Patient with purely traumatic, infectious or neoplastic origin ulcer
* Patient with a diabetic neuropathy of lower limbs
* Patient with a known allergy to one of Physiotulle or Urgotul components
* Patient already participating in another clinical study
* Pregnant or breastfeeding patient

Patient who have been taking corticoids \> 10mg / day or cytostatics by systematic way for the three months prior to inclusion

Patient who have undergone surgery of saphenous trunk in the two months prior to inclusion
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Coloplast A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bispebjerg ^Hospital

Bispebjerg, NV, Denmark

Site Status

Arhus Sygehus

Aarhus, , Denmark

Site Status

Odense Universitets Hospital

Odense, , Denmark

Site Status

Cabilet Medical

Abbeville, , France

Site Status

CHU Sud

Amiens, , France

Site Status

Cabinet Medical

Angoulême, , France

Site Status

Centre Hospitalier

Arras, , France

Site Status

Cabinet Médical

Bagnoles-de-l'Orne, , France

Site Status

CHU

Brest, , France

Site Status

CHU

Caen, , France

Site Status

Hôpital Manchester

Charlevilles Mézières, , France

Site Status

Centre Hospitalier de Douai

Douai, , France

Site Status

CHIVA

Foix, , France

Site Status

Hôpital de Freyming

Freyming Merleback, , France

Site Status

Centre Hospitalier

Haguenau, , France

Site Status

Hôpital Corention Celton

Issy-les-Moulineaux, , France

Site Status

CHD Les Oudairies

La Roche-sur-Yon, , France

Site Status

CH Le Mans

Le Mans, , France

Site Status

Cabinet Medical

Lille, , France

Site Status

Hôpital Dupuytren

Limoges, , France

Site Status

Cabinet Médical

Lunéville, , France

Site Status

Hôpital jacques Monod

Montivilliers, , France

Site Status

CHU Caremeau

Nîmes, , France

Site Status

Hôpital lariboisiere

Paris, , France

Site Status

CHRU La Miletrie

Poitiers, , France

Site Status

CH Cornouailles

Quimper, , France

Site Status

Clinique Mathilde

Rouen, , France

Site Status

Hôpital de Saint Gaudens

Saint-Gaudens, , France

Site Status

Centre hospitalier intercommunal

Saint-Germain-en-Laye, , France

Site Status

Cabinet Medical

Sarrebourg, , France

Site Status

HIA Sainte Anne

Toulon, , France

Site Status

Clinique Pasteur

Toulouse, , France

Site Status

CHRU Tours

Tours, , France

Site Status

CH

Valenciennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FR010WS

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PluroGel on Wounds of Mixed Etiology
NCT03275831 TERMINATED NA